222 related articles for article (PubMed ID: 25773234)
1. Insulin biosimilars: the impact on rapid-acting analogue-based therapy.
Franzè S; Cilurzo F; Minghetti P
BioDrugs; 2015 Apr; 29(2):113-21. PubMed ID: 25773234
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins.
Chen W; Lu J; Plum-Mörschel L; Andersen G; Zijlstra E; He A; Xie T; Li L; Hao C; Gan Z; Heise T
Diabetes Obes Metab; 2023 Dec; 25(12):3817-3825. PubMed ID: 37735841
[TBL] [Abstract][Full Text] [Related]
3. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
[TBL] [Abstract][Full Text] [Related]
4. The regulatory framework of biosimilars in the European Union.
Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
[TBL] [Abstract][Full Text] [Related]
5. [Current concept of insulin therapy intensification, and the role of human regular insulin and rapid-acting insulin analogs in insulin treatment].
Hamaguchi T; Sadahiro K; Satoh T
Nihon Rinsho; 2015 Mar; 73(3):447-52. PubMed ID: 25812371
[TBL] [Abstract][Full Text] [Related]
6. [Practical aspects in the use of biosimilar insulins].
Krämer I; Blüher M; Kuhlmann MK; Heinemann L
Dtsch Med Wochenschr; 2016 Oct; 141(21):1565-1568. PubMed ID: 27750344
[TBL] [Abstract][Full Text] [Related]
7. The advent of biosimilars for the treatment of diabetes: current status and future directions.
Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar insulins.
Heinemann L
Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
[TBL] [Abstract][Full Text] [Related]
9. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
Rasmussen JT; Ipema HJ
Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
[TBL] [Abstract][Full Text] [Related]
10. The biosimilar insulin landscape: current developments.
Lavalle-González FJ; Khatami H
Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
[TBL] [Abstract][Full Text] [Related]
11. SAR342434 - an insulin biosimilar for the treatment of type II diabetes.
Hu J; Wang M; Zhao Y
Expert Opin Biol Ther; 2018 Nov; 18(11):1107-1112. PubMed ID: 30295083
[TBL] [Abstract][Full Text] [Related]
12. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review.
Kerr D; Wizemann E; Senstius J; Zacho M; Ampudia-Blasco FJ
J Diabetes Sci Technol; 2013 Nov; 7(6):1595-606. PubMed ID: 24351186
[TBL] [Abstract][Full Text] [Related]
13. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
[TBL] [Abstract][Full Text] [Related]
14. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
[TBL] [Abstract][Full Text] [Related]
15. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
16. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
17. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
18. Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart.
Ghade NS; Thappa DK; Lona J; Krishnan AR; Sonar SM
Sci Rep; 2024 Feb; 14(1):4224. PubMed ID: 38378730
[TBL] [Abstract][Full Text] [Related]
19. Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.
Heinemann L; Davies M; Home P; Forst T; Vilsbøll T; Schnell O
J Diabetes Sci Technol; 2023 Nov; 17(6):1649-1661. PubMed ID: 35818669
[TBL] [Abstract][Full Text] [Related]
20. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
Front Public Health; 2021; 9():671961. PubMed ID: 34249838
[No Abstract] [Full Text] [Related]
[Next] [New Search]
